0.05Open0.10Pre Close1.54K Volume6.47K Open Interest2.00Strike Price3.19KTurnover364.94%IV0.99%PremiumJul 19, 2024Expiry Date0.02Intrinsic Value100Multiplier0DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.6153Delta5.2402Gamma50.50Leverage Ratio-0.4003Theta0.0000Rho31.07Eff Leverage0.0001Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet